password
username
Sponsored by CakeMail, an email marketing software.
Newsletter preview

N I D C D, the National Institute on Deafness and Other Communication Disorders

June 1, 2007

Blood Test May Help Signal Tumor’s Remission, Return in Throat Cancer Patients

A blood test that detects proteins commonly released by a growing tumor could one day become a useful tool for monitoring the effectiveness of chemotherapy and radiation treatment in people with advanced throat cancer, according to a study published in the June 1, 2007, issue of Clinical Cancer Research. Scientists in the National Institute on Deafness and Other Communication Disorders (NIDCD) and National Cancer Institute (NCI), two of the National Institutes of Health (NIH), in collaboration with researchers of the University of Michigan, found that throat cancer patients who showed a decline in several cancer-related proteins following chemotherapy and radiation treatment were more likely to remain in remission, while those who experienced a large rise over time in those proteins frequently exhibited a return of throat cancer. The findings could help lead to the development of a blood test that enables doctors to detect the recurrence of throat cancer early on, when there is still time to pursue a second line of treatment, such as surgery or drug therapy.

Learn More


NIDCD supports and conducts research and research training on the normal and disordered processes of hearing, balance, smell, taste, voice, speech, and language and provides health information, based upon scientific discovery, to the public. For more information about NIDCD programs, see the Web site at www.nidcd.nih.gov.

If you would like to *** from this service, please visit http://www.nidcd.nih.gov/subscription/***.asp.